{"schema_version":"secwatch.filing_event.v1","accession":"0001576280-24-000260","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.847213+00:00","generated_at":"2026-05-30T04:32:56.661944+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Guardant Health Q3 revenue $191.5M (+34% YoY); raises FY 2024 revenue guidance to $720-725M","bullets":["Revenue $191.5M (+34% YoY); GAAP net loss $107.8M ($0.88/shr), Non-GAAP net loss $55.0M ($0.45/shr).","Clinical test volume 53,100 (+21%), biopharma 10,500 (+40%); Guardant360 ASP >$3,000.","Full-year 2024 revenue guidance raised to $720-725M (prior $690-700M), growth 28-29%.","Free cash flow guidance improved to $(265)-$(275)M, improvement of $70-80M vs 2023.","Shield IVD launched; received Medicare pricing of $920; CMS removed cost-sharing for follow-on colonoscopy."],"urls":{"canonical":"https://secwatch.observer/filing/0001576280-24-000260","json":"https://secwatch.observer/filing/0001576280-24-000260.json","markdown":"https://secwatch.observer/filing/0001576280-24-000260.md","text":"https://secwatch.observer/filing/0001576280-24-000260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000157628024000260/0001576280-24-000260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000157628024000260/gh-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:32:56.661944+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}